Skip to content
10-Q

Quarterly Report

Cellectar Biosciences, Inc. CLRB

0001104659-26-060678

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 12, 2026 7.99M sh
Shares Diluted Q1 2026 · Mar 31, 2026 4.24M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 1.54M sh
Capex Q1 2026 · Mar 31, 2026 $3.38K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.85M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$9.38M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $8.35M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $13.2M
Stockholders Equity Q1 2026 · Mar 31, 2026 $3.34M
Stockholders Equity Q1 2026 · Dec 31, 2025 $8.54M
Stockholders Equity Q1 2026 · Mar 31, 2025 $8.25M
Stockholders Equity Q1 2026 · Dec 31, 2024 $14.29M
Current Liabilities Q1 2026 · Mar 31, 2026 $4.87M
Current Liabilities Q1 2026 · Dec 31, 2025 $4.75M
Total Liabilities Q1 2026 · Mar 31, 2026 $6.4M
Total Liabilities Q1 2026 · Dec 31, 2025 $5.06M
Current Assets Q1 2026 · Mar 31, 2026 $9.27M
Current Assets Q1 2026 · Dec 31, 2025 $14.04M
Total Assets Q1 2026 · Mar 31, 2026 $11.12M
Total Assets Q1 2026 · Dec 31, 2025 $14.98M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.33
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$4.30
Eps Basic Q1 2026 · Mar 31, 2026 −$1.33
Eps Basic restated Q1 2026 · Mar 31, 2025 −$4.30
Sga Expense Q1 2026 · Mar 31, 2026 $2.79M
Sga Expense Q1 2026 · Mar 31, 2025 $2.97M
Rd Expense Q1 2026 · Mar 31, 2026 $3.01M
Rd Expense Q1 2026 · Mar 31, 2025 $3.43M
Net Income Q1 2026 · Mar 31, 2026 −$5.65M
Net Income Q1 2026 · Mar 31, 2025 −$6.6M
Operating Income Q1 2026 · Mar 31, 2026 −$5.79M
Operating Income Q1 2026 · Mar 31, 2025 −$6.4M